Tirzepatide
30mg
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This 39-amino acid synthetic peptide is based on the native GIP sequence with modifications that confer GLP-1 receptor co-agonism. A C20 fatty diacid moiety linked through a glutamic acid and two mini-PEG spacers enhances albumin binding, resulting in a half-life suitable for once-weekly dosing. Tirzepatide has demonstrated superior glycemic control and weight reduction compared to selective GLP-1 receptor agonists in clinical trials.
Select Option
10% OFF · ends July 31Out of Stock
Notify me when back in stock
We'll email you the moment Tirzepatide is available.
Mechanism of Action
Tirzepatide engages both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) with a bias toward GIPR agonism (~5:1 ratio). GIPR activation in adipose tissue modulates lipid storage and adipokine secretion, while central GIPR signaling may contribute to appetite suppression independently of GLP-1 pathways. The combined receptor engagement produces synergistic effects on insulin secretion, glucagon suppression, and energy expenditure that exceed those of selective GLP-1R agonism alone.
Properties
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.45 Da
Half-Life
~5 days
Storage
Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.
Research Applications
References & Citations
(3)Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías JP, Davies MJ, Rosenstock J, et al.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
Malhotra A, Grunstein RR, et al.
Related Products
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.